PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA

This early-phase study tests a new drug called SGR-1505 in about 98 adults with various B-cell blood cancers (like lymphoma and leukemia). The main goals are to check safety and find the best dose. Participants will receive the drug and be monitored for side effects and how the d…

This study tests whether adding the drug pembrolizumab to standard CAR-T cell therapy can improve outcomes for people with a rare type of lymphoma (PMBCL) that has come back or not responded to prior treatment. About 35 adults will receive the combination and be monitored for 6 m…

This early-phase study tests whether adding the targeted drug polatuzumab vedotin (with or without another drug, glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to see how well …

This early-phase study tests whether a personalized cell therapy (CAR-T cells) is safe for people with certain types of Non-Hodgkin lymphoma that have come back or not responded to standard treatments. Up to 36 participants will receive their own immune cells that have been genet…

This study tests whether the drug emapalumab can prevent severe cytokine release syndrome (CRS), a common and serious side effect of CAR-T cell therapy, in adults with certain types of non-Hodgkin lymphoma that have come back or not responded to treatment. About 28 participants w…

This study tests whether adding the drug epcoritamab to standard chemotherapy (EPOCH-R) is safe and effective for people with aggressive B-cell non-Hodgkin lymphoma. About 18 participants will receive the combination as their first treatment. The goal is to improve cancer remissi…

This study looks at whether CAR-T cell therapy, a treatment for certain blood cancers, reduces the protection that past vaccines (like measles or tetanus shots) provide. Researchers will test the blood of 45 adults with multiple myeloma or non-Hodgkin lymphoma before and after CA…